Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease Life Science Investing
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025 Life Science Investing
ABVC BioPharma Highlights Safety Profile of Its Plant-Based ADHD Candidate Amid Growing Concerns About Psychiatric Polypharmacy in the United States Life Science Investing
AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers Pharmaceutical Investing
Pfizer Invites Public to View and Listen to Webcast of December 16 Conference Call with Analysts to Provide Full-Year 2026 Financial Guidance Pharmaceutical Investing
New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions Biotech Investing
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio Life Science Investing
SKYRIZI® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance Pharmaceutical Investing
